BMY Stock Recent News
BMY LATEST HEADLINES
#Morningstar #MicrosoftStock #StockInvesting These undervalued stocks have defensive qualities that make them attractive in today's market. 00:00 Introduction 00:43 Bristol Myers Squibb BMY 01:22 Campbell Soup CPB 02:11 Microsoft MSFT I'm Susan Dziubinski with Morningstar.
Bristol Myers (BMY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Brookfield Renewable Partners offers a juicy dividend yield that could rise steadily along with electricity demand. Royalty Pharma's portfolio of pharmaceutical products is growing by leaps and bounds, and so is its dividend payout.
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #10year--Bristol Myers Squibb Presents Landmark 10-Year Follow-Up Data from CheckMate -067 Which Showed Continued Durable Long-Term Survival Benefit.
Bristol Myers Squibb and Gilead Sciences are longtime healthcare leaders. Both have the innovative abilities needed to continue developing new drugs.
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb Announces Dividend.
BMY's rally from the July 2024 bottom is well deserved, as the market rotated from high growth to high dividend-yielding sectors. This is significantly aided by the pharmaceutical company's robust FQ2'24 performance and raised FY2024 guidance. Readers must not forget the numerous tailwinds from H2'24 to 2026 as BMY increasingly monetizes its in-house/acquired pipelines.
A bear market could be around the corner, but it probably won't stop Bristol Myers Squibb and Royalty Pharma from rapidly raising their dividend payouts. Bristol Myers Squibb has increased its dividend payout by 46% over the past five years.
Bristol-Myers Squibb delivered a significant earnings beat in Q2, driving shares up 20% since spring and boosting sector performance. Despite concerns about long-term EPS, strong Q2 results and improved guidance support a buy rating, with a valuation target near $76. BMY's technical chart shows bullish signals, including a potential golden cross and improved RSI momentum, indicating a favorable trend.
Bristol-Myers Squibb Company (NYSE:BMY ) Wells Fargo 2024 Healthcare Conference September 6, 2024 12:00 AM ET Company Participants Adam Lenkowsky - Chief Commercialization Officer Conference Call Participants Mohit Bansal - Wells Fargo Cerena Chen - Wells Fargo Mohit Bansal All right. Good morning on a Friday.